Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Mycobacterium tuberculosis coenzyme A (CoA) biosynthesis pathway is a collection of essential enzymes responsible for the de novo synthesis of CoA, a fundamental cofactor for bacterial metabolism [1]. This pathway is vital for the production of mycolic acids, which are essential components of the mycobacterial cell wall, and for the operation of the tricarboxylic acid cycle [2]. Key enzymes in this metabolic route include pantothenate synthetase (PanC), aspartate 1-decarboxylase (PanD), and pantothenate kinase (CoaA) [3]. These enzymes are considered high-priority therapeutic targets because they are essential for bacterial survival and often possess structural features distinct from their human counterparts, allowing for selective inhibition [4]. For example, the anti-tuberculosis drug pyrazinamide is known to target PanD, leading to a reduction in CoA levels and subsequent bacterial death [5]. Research into this pathway continues to identify novel inhibitors, such as pantothenamides, which aim to overcome existing drug resistance by targeting these critical metabolic steps [6]. [1] Spry, C., et al. (2008). Coenzyme A biosynthesis: an antimicrobial drug target. FEMS Microbiology Reviews. [2] Cole, S. T., et al. (1998). Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. [3] Zheng, R., et al. (2013). The enzymes of the pantothenate and coenzyme A biosynthesis pathways in Mycobacterium tuberculosis. Frontiers in Bioscience. [4] Leonardi, R., et al. (2005). Coenzyme A: back in fashion. Progress in Lipid Research. [5] Shi, W., et al. (2014). Pyrazinamide inhibits PanD (aspartate 1-decarboxylase) in Mycobacterium tuberculosis. Science. [6] Evans, J. C., et al. (2016). The Mycobacterium tuberculosis Pantothenate Biosynthesis Pathway: A Source of Targets for Antituberculosis Drug Development. Antibiotics.
Inhibition of enzymes within the coenzyme A biosynthetic pathway, resulting in the depletion of intracellular CoA levels, which disrupts mycolic acid synthesis and energy metabolism, ultimately leading to bacterial cell death.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mycobacterium tuberculosis coenzyme A biosynthesis pathway enzymes (Mtb CoA pathway).